Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
:0HD2
Alnylam Pharma (0HD2) Ownership Overview
0.38% Insiders
49.21% Mutual Funds
0.20% Other Institutional Investors
15.19% ETFs
35.01% Public Companies and
Individual Investors
The ownership structure of Alnylam Pharma (GB:0HD2) stock is a mix of institutional, retail, and individual investors. Approximately 64.60% of the company’s stock is owned by Institutional Investors, 0.38% is owned by Insiders, and 35.01% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Mar 05, 2025 | Yvonne Greenstreet Ceo,director | xxxxxxxxxxxxx | $945165 |
| Mar 05, 2025 | Jeffrey V. Poulton Evp & Cfo | xxxxxxxxxxxxx | $308141 |
| Mar 05, 2025 | Fitzgerald Kevin Joseph Cso & Evp, Head Of Research | xxxxxxxxxxxxx | $180402 |
| Mar 05, 2025 | Tolga Tanguler Evp & Cco | xxxxxxxxxxxxx | $114820 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2024 | xxxxxxxxxxxxx | $552978 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $598158 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $1518220 | |
| Dec 31, 2024 | xxxxxxxxxxxxx | $1647170 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 12,130,914 | Institution | 9.37% | 3,036,307,120 | |
| 11,207,249 | Institution | 8.66% | 2,805,118,388 | |
| 10,568,306 | Institution | 8.16% | 2,645,194,150 | |
| 4,208,176 | Institution | 3.25% | 1,053,285,412 | |
| 3,731,045 | Institution | 2.88% | 933,861,908 | |
| 3,709,512 | Institution | 2.87% | 928,472,306 | |
| 3,616,776 | Institution | 2.79% | 905,260,949 | |
| 3,540,262 | Institution | 2.73% | 886,109,877 | |
| 2,781,241 | Institution | 2.15% | 696,130,716 | |
| 2,371,756 | Institution | 1.83% | 593,638,668 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 11,207,249 | Institution | 8.66% | 2,805,118,388 | |
| 10,568,306 | Institution | 8.16% | 2,645,194,150 | |
| 3,731,045 | Institution | 2.88% | 933,861,908 | |
| 3,709,512 | Institution | 2.87% | 928,472,306 | |
| 3,616,776 | Institution | 2.79% | 905,260,949 | |
| 2,781,241 | Institution | 2.15% | 696,130,716 | |
| 2,371,756 | Institution | 1.83% | 593,638,668 | |
| 2,230,663 | Institution | 1.72% | 558,323,796 | |
| 1,882,997 | Institution | 1.45% | 471,304,734 | |
| 1,613,894 | Institution | 1.25% | 403,949,599 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Alnylam Pharmaceuticals (GB:0HD2)?
According to the latest TipRanks data, approximately 0.20% of the company's stock is held by institutional investors, 0.38% is held by insiders, and 35.01% is held by retail investors.
What percentage of Alnylam Pharmaceuticals (GB:0HD2) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.20% of Alnylam Pharmaceuticals (GB:0HD2) stock is held by institutional investors.
What percentage of Alnylam Pharmaceuticals (GB:0HD2) stock is held by retail investors?
According to the latest TipRanks data, approximately 35.01% of Alnylam Pharmaceuticals (GB:0HD2) stock is held by retail investors.
Who owns the most shares of Alnylam Pharmaceuticals (GB:0HD2)?
Vanguard owns the most shares of Alnylam Pharmaceuticals (GB:0HD2).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.